Anticoagulation in special patient populations: are special dosing considerations required?

Designing and Implementing a Practical Course of "Pharmacotherapy in Special Populations" for Medical Interns

Introduction: Learning how to use medications rationally is an important and key issue in medical education. The aims of this study were needs assessment, designing and implementing practical training on pharmacotherapeutic issues in special populations (pregnant women, nursing mothers who are breast-feeding, infants, and elders) for medical interns. Methods: This study was conducted in two con...

Evidence-based drug treatment for special patient populations through model-based approaches.

The majority of marketed drugs remain understudied in some patient populations such as pregnant women, paediatrics, the obese, the critically-ill, and the elderly. As a consequence, currently used dosing regimens may not assure optimal efficacy or minimal toxicity in these patients. Given the vulnerability of some subpopulations and the challenges and costs of performing clinical studies in the...

Dosing of Target-Specific Oral Anticoagulants in Special Populations.

OBJECTIVE To review current literature for target-specific oral anticoagulants (TSOACs) and provide critical analysis for dosing recommendations in special population groups. DATA SOURCES A literature search was conducted in Medline (1996 to April week 2 2015) and Embase (1980 to 2015 week 16) using key terms dabigatran, rivaroxaban, apixaban, edoxaban, kidney diseases, liver diseases, elderl...

Special Considerations in Air Travel for Pregnant Women

Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation – patient considerations

The direct factor Xa inhibitor rivaroxaban was the first within the group of orally available direct factor Xa inhibitors to gain clinical approval for oral anticoagulation in patients with nonvalvular atrial fibrillation in 2011. The -xabans, as drugs from the group of oral direct factor Xa inhibitors are often referred to, comprise currently three drugs (apixaban, edoxaban, and rivaroxaban) w...